WebDec 24, 1996 · Evaluation of the activity profile using the COMPARE program revealed a different pattern for both agents: the cisplatin activity profile was similar to those of other diamine-platinum compounds, alkylating agents including melphalan, and camptothecin analogs, whereas the activity profile of oxaliplatin resembled those of other "dach" … WebFeb 18, 2014 · Moreover, cisplatin is difficult to administer because prolonged intravenous hydration is necessary, and so more convenient and safer schedules should be investigated to improve outcome.
Oxaliplatin - Wikipedia
WebDiscussion. In a previous study, we showed that DM was the high-risk factor for cisplatin-induced AKI. 5 However, no attempt was made to identify the mechanism for the development of AKI in patients with DM. MATE1/SLC47A1, an organic cation transporter in proximal tubular epithelial cells, mediates the tubular secretion of cationic drugs or … WebApr 4, 2024 · Carboplatin belongs to a class of medications known as platinum-containing compounds. It works by stopping or slowing the growth of cancer cells. Carboplatin is used in adults in combination with other cancer treatments to treat ovarian cancer. is abortion the best option
Review of the Comparative Pharmacology and Clinical Activity of ...
Web/Bevacizumab PACLitaxel Bevacizumab CARBOplatin N/A 151 CISplatin/5-FU CISplatin 5-FU 5-FU as CIVI 46 CISplatin/Gemcitabine Gemcitabine CISplatin Less toxic 47 ... OXALIplatin Leucovorin 5-FU IV push Push 5-FU 1 hour into leucovorin infusion 55 . 5-FU/Leucovorin/OXALIpl atin (FOLFOX) OXALIplatin+Leucov WebJul 22, 2024 · Cisplatin is a potent and valuable chemotherapy agent used to treat a broad spectrum of malignancies. Renal tubular dysfunction and a cumulative impairment in kidney function, as manifested by a decline in the glomerular filtration rate (GFR), can be … WebMay 28, 2024 · Results: 801 LS-SCLC patients who received carboplatin-based therapy (Carbo-SCLC) and 1018 who cisplatin-based therapy (Cis-SCLC) were included in the analysis. Median OS with Carbo-SCLC and Cis-SCLC were 2.13 years (95% CI 1.97-2.31) and 2.24 years (95% CI 2.09-2.4), respectively (HR=1.04;95% CI, 0.94-1.16; p=0.46). old stock a refugee love story ottawa